Table of Content

1. Market Introduction and Scope
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. Executive Insights and Key Takeaways
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Therapy
2.4. Snippet by End-User
3. Dynamics
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Rising Demand for Advanced Therapies
3.1.1.2. Rising Adoption of Combination Therapies
3.1.1.3. XX
3.1.2. Restraints
3.1.2.1. Limited Efficacy of Current Therapies
3.1.2.2. High Cost of Treatment for Locally Advanced Pancreatic Cancer
3.1.2.3. XX
3.1.3. Opportunity
3.1.3.1. AI and Big Data Analytics in Cancer Treatment
3.1.3.2. XX
3.1.4. Impact Analysis
4. Strategic Insights and Industry Outlook
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established leaders with the largest-selling Brand
4.1.3. Market leaders with established Product
4.2. CXO Perspectives
4.3. Latest Developments and Breakthroughs
4.4. Case Studies/Ongoing Research
4.5. Regulatory and Reimbursement Landscape
4.6. Porter’s Five Forces Analysis
4.7. Supply Chain Analysis
4.8. Patent Analysis
4.9. SWOT Analysis
4.10. Unmet Needs and Gaps
4.11. Recommended Strategies for Market Entry and Expansion
4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
4.13. Pricing Analysis and Price Dynamics
4.14. Key Opinion Leaders
5. North America Locally Advanced Pancreatic Cancer Market, By Therapy
5.1. Introduction
5.1.1. Analysis and Y-o-Y Growth Analysis (%), By Therapy
5.1.2. Market Attractiveness Index, By Therapy
5.2. Chemotherapy*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.2.3. Folfirinox
5.2.4. Gemcitabine
5.2.5. Nab-Paclitaxel
5.2.6. Cisplatin
5.2.7. Others
5.3. Surgery
5.3.1. Whipple Procedure
5.3.2. Distal Pancreatectomy
5.3.3. Total Pancreatectomy
5.4. Radiation Therapy
5.5. Targeted Therapy
5.5.1. Larotrectinib
5.5.2. Entrectinib
5.6. Immunotherapy
6. North America Locally Advanced Pancreatic Cancer Market, By End-User
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
6.1.2. Market Attractiveness Index, By End-User
6.2. Hospitals*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Specialty Clinics
6.4. Research Institutions
7. Competitive Landscape and Market Positioning
7.1. Competitive Overview and Key Market Players
7.2. Market Share Analysis and Positioning Matrix
7.3. Strategic Partnerships, Mergers & Acquisitions
7.4. Key Developments in Product Portfolios and Innovations
7.5. Company Benchmarking
8. Company Profiles
8.1. BRISTOL-MYERS SQUIBB COMPANY
8.1.1. Company Overview
8.1.2. Product Portfolio
8.1.2.1. Product Description
8.1.2.2. Product Key Performance Indicators (KPIs)
8.1.2.3. Historic and Forecasted Product Sales
8.1.2.4. Product Sales Volume
8.1.3. Financial Overview
8.1.3.1. Company Revenue’s
8.1.3.2. Geographical Revenue Shares
8.1.3.3. Revenue Forecasts
8.1.4. Key Developments
8.1.4.1. Mergers & Acquisitions
8.1.4.2. Key Product Development Activities
8.1.4.3. Regulatory Approvals, etc.
8.1.5. SWOT Analysis
8.2. Pfizer Inc.
8.3. Merck & Co., Inc.
8.4. Fresenius Kabi AG
8.5. Teva Pharmaceutical Industries Ltd
8.6. F. Hoffmann-La Roche Ltd.*
8.7. Sun Pharmaceutical Industries Ltd.
8.8. Merus N.V.
8.9. CHEPLAPHARM Arzneimittel GmbH
8.10. Bayer AG
LIST NOT EXHAUSTIVE
9. Assumptions and Research Methodology
9.1. Data Collection Methods
9.2. Data Triangulation
9.3. Forecasting Techniques
9.4. Data Verification and Validation
10. Appendix
10.1. About Us and Services
10.2. Contact Us